NTLA: Intellia Corp Forward P/S Multiple

Corporate emblem and logo of Intellia (NTLA)

Intellia Therapeutics (NTLA) is developing scientific alliances with biotech leaders to create therapies for rare pathologies. The current forward P/S level on the GURU.Markets dynamic chart shows 25.60, which determines the current status of the parameter. The asset is independent of GDP cycles, relying instead on the success of clinical trials, while growth is based on organic R&D and support from pharmaceutical industry behemoths.

Intellia Therapeutics, Inc. - NTLA Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for intelliatx.com (NTLA)

Fundamental valuation:intelliatx.com NTLA
Product sample of Intellia Therapeutics

Intellia Therapeutics (NTLA) is scaling CRISPR/Cas9 technologies to create global blockbusters for the treatment of rare liver pathologies. The forward P/S ratio measures the market value of the business relative to projected annual sales volume. By analyzing the projected price-to-sales ratio on GURU.Markets, an investor separates market noise from the actual growth in revenue expectations. The dynamics of this indicator determine the balance between return potential and the asset's sensitivity to fundamental risks.

Competitor analysis

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|Stoke Corp - Forward P/S Multiple|BLFS (BioLife) - Market Cap to Projected Revenue|wavelifesciences.com (WVE) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prime Medicine Corp (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.